NEW YORK , March 3, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it has selected inVentiv Clinical Solutions to manage its Phase III pivotal trial with Iferanserin
NEW YORK , Feb. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison , the company's president and chief executive officer will be presenting at the
NEW YORK , Feb. 1, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the completion of its clinical development staffing. Ventrus has contracted Mohan Kabadi , Ph.D.
Underwriters Exercise Over-Allotment Option for Ventrus Biosciences' Initial Public Offering NEW YORK, Jan. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced
Ventrus Biosciences Announces Closing of Initial Public Offering of Common Stock NEW YORK, Dec. 23, 2010 (GLOBE NEWSWIRE) -- Ventrus Biosciences Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it
Ventrus Biosciences Announces Pricing of Its Initial Public Offering NEW YORK, Dec. 16, 2010 (GLOBE NEWSWIRE) -- Ventrus Biosciences Inc. ("Ventrus") (Nasdaq: VTUS ), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its
